Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Withdrawn | |||
| Velsipity | etrasimod | Ulcerative colitis | Active | |||
| Apretude | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
| Jemperli | dostarlimab | Endometrial cancer | Active | |||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Received | |||
| Repatha | evolocumab | Primary hyperlipidemia | Active | |||
| Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Pending | |||
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete |
Last Updated : May 17, 2024